Title:
USE OF EGFR KINASE INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2024/046405
Kind Code:
A1
Abstract:
Provided is use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in treating advanced or metastatic NSCLC.
Inventors:
GUAN DONGMEI (CN)
XU YANAN (CN)
ZHANG BASHENG (CN)
FANG LIANGHUA (CN)
ZHENG SHANSONG (CN)
TIAN MIN (CN)
XU YANAN (CN)
ZHANG BASHENG (CN)
FANG LIANGHUA (CN)
ZHENG SHANSONG (CN)
TIAN MIN (CN)
Application Number:
PCT/CN2023/116001
Publication Date:
March 07, 2024
Filing Date:
August 31, 2023
Export Citation:
Assignee:
QILU PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K31/55; A61K31/498; A61K31/506; A61P35/00
Domestic Patent References:
| WO2023061434A1 | 2023-04-20 | |||
| WO2023061433A1 | 2023-04-20 | |||
| WO2021208918A1 | 2021-10-21 | |||
| WO2021190417A1 | 2021-09-30 | |||
| WO2020216371A1 | 2020-10-29 |
Foreign References:
| CN110652514A | 2020-01-07 |
Other References:
HE, JIE ET AL.: "The New Opportunities in Medicinal Chemistry of Fourth-Generation EGFR Inhibitors to Overcome C797S Mutation", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 210, 16 November 2020 (2020-11-16), XP086432089, DOI: 10.1016/j.ejmech.2020.112995
JINGJING CAI, ZHOU YONGCHUN: "New Progress of the resistance mechanism and therapeutic strategies of the third-generation EGFR-TKIs in NSCLC", THE JOURNAL OF PRACTICAL MEDICINE, vol. 35, no. 4, 25 February 2019 (2019-02-25), pages 512 - 515, XP093145000, DOI: 10.3969/j.issn.1006•5725.2019.04.002
JINGJING CAI, ZHOU YONGCHUN: "New Progress of the resistance mechanism and therapeutic strategies of the third-generation EGFR-TKIs in NSCLC", THE JOURNAL OF PRACTICAL MEDICINE, vol. 35, no. 4, 25 February 2019 (2019-02-25), pages 512 - 515, XP093145000, DOI: 10.3969/j.issn.1006•5725.2019.04.002
Download PDF:
Previous Patent: RECOMBINANT BOTULINUM TOXIN AND PREPARATION METHOD THEREFOR
Next Patent: ALKYLIDENE CARBAMATE AS KRAS INHIBITORS
Next Patent: ALKYLIDENE CARBAMATE AS KRAS INHIBITORS